<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901379</url>
  </required_header>
  <id_info>
    <org_study_id>LB.02.01/VII/090/KEP.013/2016</org_study_id>
    <nct_id>NCT02901379</nct_id>
  </id_info>
  <brief_title>Effect of 80-mg Atorvastatin on Myocardial Edema</brief_title>
  <official_title>Effect of 80-mg Atorvastatin on Myocardial Edema Following Coronary Artery Bypass Surgery in Relation With Follistatin-Like Protein-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cardiovascular Center Harapan Kita Hospital Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cardiovascular Center Harapan Kita Hospital Indonesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether atorvastatin 80mg can reduce the&#xD;
      development of myocardial edema following coronary artery bypass surgery.&#xD;
&#xD;
      This study also want to determine:&#xD;
&#xD;
        1. whether atorvastatin 80mg can influence Follistatin-like 1 (FSTL1) plasma level&#xD;
           following bypass surgery?&#xD;
&#xD;
        2. whether there is correlation between myocardial edema and FSTL1 plasma level?&#xD;
&#xD;
        3. the efficacy of atorvastatin 80mg compared to atorvastatin 10mg in reducing hs-CRP (high&#xD;
           sensitive-C reactive protein) and MDA (malondialdehyde) plasma level following bypass&#xD;
           surgery?&#xD;
&#xD;
        4. the efficacy of atorvastatin 80mg compared to atorvastatin 10mg in raising PKA and PKB&#xD;
           plasma level following bypass surgery?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an double blinded experimental study using parallel design. Study subjects are&#xD;
      patients in Harapan Kita hospital who are registered to CABG (Coronary Artery Bypass Graft)&#xD;
      surgery and fulfill all the eligibility criteria.&#xD;
&#xD;
      The subjects will be first consecutively selected, with male age 40-65 as the criteria. After&#xD;
      that the investigators do the randomization with block randomization method. All the subjects&#xD;
      will be given drug with label A and label B (only the pharmacist know the which dose of&#xD;
      atorvastatin belong to which label).&#xD;
&#xD;
      Total subjects needed for this study are 30 (15 belong to study group and 15 belong to&#xD;
      control group) MRI (Magnetic Resonance Imaging) results will be read by two radiologists, and&#xD;
      analyzed using cronbach alpha. The results are considered equal if the cronbach &gt;0,7. If it&#xD;
      is proven to be unequal, then the third radiologist will decide.&#xD;
&#xD;
      Statin is known to have several adverse effects, such as myopathy, myositis to&#xD;
      rhabdomyolysis, elevated liver enzyme, memory loss, GI (gastrointestinal) disturbance, and&#xD;
      severa others. Therefore, the investigators will check baseline CK (creatine kinase) and&#xD;
      liver enzyme at the beginning of the study, before the surgery, and if the patient feel any&#xD;
      symptoms. Statin will be stopped if patient decide to stop, or if there is increase in ALT&#xD;
      (alanine aminotransferase) higher that three time upper normal value, or if there is increase&#xD;
      in CK higher than ten times upper normal value.&#xD;
&#xD;
      Statistical analysis using IBM SPSS statistics version 21.0. Comparative analysis for&#xD;
      variables such as smoking history, obesity, hypertension, dyslipidemia, diabetes, family&#xD;
      history, infarct history, ACE-I/ARB (angiotensin converting enzyme inihibitor /angiotensin&#xD;
      receptor blocker) therapy will be using chi-square or fischer. Comparative analysis for&#xD;
      variables T2 relaxation time, FSTL1, hs-CRP, PKA (protein kinase A), PKB (Protein Kinase B),&#xD;
      MDA, age, CPB (Cardiopulmonary Bypass) time, CABG time will using unpaired t-test or&#xD;
      Mann-whitney. Correlative analysis between FSTL1 and T2 relaxation time will be using Pearson&#xD;
      test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T2 relaxation time</measure>
    <time_frame>day 6 after CABG</time_frame>
    <description>T2 relaxation time (in ms) difference between control and study group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FSTL1 plasma level</measure>
    <time_frame>day 6 after CABG</time_frame>
    <description>FSTL1 plasma level difference between control and study group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PKA plasma level</measure>
    <time_frame>day 6 after CABG</time_frame>
    <description>PKA plasma level difference between control and study group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PKB plasma level</measure>
    <time_frame>day 6 after CABG</time_frame>
    <description>PKB plasma level difference between control and study group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP plasma level</measure>
    <time_frame>day 1 after CABG</time_frame>
    <description>hs-CRP plasma level difference between control and study group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDA plasma level</measure>
    <time_frame>day 1 after CABG</time_frame>
    <description>MDA plasma level difference between control and study group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline FSTL1 plasma level</measure>
    <time_frame>day 1 and day 6 after CABG</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline PKA plasma level</measure>
    <time_frame>day 1 and day 6 after CABG</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline PKB plasma level</measure>
    <time_frame>day 1 and day 6 after CABG</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Myocardial Edema</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who will receive atorvastatin 80mg for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject who will receive atorvastatin 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80mg</intervention_name>
    <description>Subject will be given atorvastatin 80mg for two weeks</description>
    <arm_group_label>Atorvastatin 80mg</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10mg</intervention_name>
    <description>Subjects will be give atorvastatin 10mg as part of standard therapy in hospital</description>
    <arm_group_label>Atorvastatin 10mg</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with coronary artery disease indicated for CABG surgery&#xD;
&#xD;
          -  has signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  high risk EURO (European System for Cardiac Operative Risk Evaluation) score&#xD;
&#xD;
          -  creatinin value&gt;2 g/dl&#xD;
&#xD;
          -  direct bilirubin value &gt;3 mg/ml&#xD;
&#xD;
          -  AST/ALT (aspartate transaminase / alanine transaminase) value &gt;1,5 times UNL (upper&#xD;
             normal limit)&#xD;
&#xD;
          -  high pre-operative CKMB (Creatine Kinase-MB) and troponin&#xD;
&#xD;
          -  LVEF (Left Ventricular Ejection Fraction) &lt;45%&#xD;
&#xD;
          -  concomitant valve disease required surgery&#xD;
&#xD;
          -  contraindicated for MRI&#xD;
&#xD;
          -  high degree ventricular arrhytmia&#xD;
&#xD;
          -  coagulation disorder&#xD;
&#xD;
          -  COPD (chronic obsructive pulmonary disease)&#xD;
&#xD;
          -  HIV (Human Immunodeficiency Virus) +, HBV (Hepatitis B Virus)+, HCV (Hepatitis C&#xD;
             Virus) +&#xD;
&#xD;
          -  conduction abnormality, pacemaker&#xD;
&#xD;
          -  electrolyte or blood gas disturbance&#xD;
&#xD;
          -  receiving immunosuppressive drug or cytotoxic agent 4 weeks before surgery&#xD;
&#xD;
          -  receiving macrolide, azole antifungal, fibrate, or protease inhibitor HIV drug&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Zahara</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cardiovascular Center Harapan Kita</affiliation>
  </overall_official>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cardiovascular Center Harapan Kita Hospital Indonesia</investigator_affiliation>
    <investigator_full_name>Rita Zahara</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <keyword>atorvastatin</keyword>
  <keyword>myocardial edema</keyword>
  <keyword>Follistatin-like 1</keyword>
  <keyword>FSTL1</keyword>
  <keyword>atorvastatin 80mg</keyword>
  <keyword>coronary artery bypass surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

